$0.00
0.00%
Nasdaq, Oct 01, 04:00 pm EDT.
ISIN
US09057N2018
Symbol
BPTH

Bio-Path Holdings, Inc. Stock price

$0.00
-0.02 99.57% 1M
-0.06 99.84% 6M
-0.06 99.83% YTD
-0.07 99.86% 1Y
-7.58 100.00% 3Y
-101.00 100.00% 5Y
-5,160.00 100.00% 10Y
-2,200.00 100.00% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
+0.00 0.00%
ISIN
US09057N2018
Symbol
BPTH
Industry

Is Bio-Path Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$10.0k
Enterprise Value
$510.0k
Net debt
$500.0k
Cash
$10.0k
Shares outstanding
9.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.4 | -
P/B
0.0
Financial Health
Equity Ratio
4.0%
Return on Equity
-6,424.7%
ROCE
63.1%
ROIC
-
Debt/Equity
-0.1
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-5.4m
EBIT
$-5.3m
Net Income
$-5.8m
Free Cash Flow | ex SBC
$1.3m | -
Growth
Revenue | estimate
- | -
EBITDA
40.1%
EBIT
40.0%
Net Income
14.6%
Free Cash Flow
557.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.6
FCF per Share
$0.1
Short interest
1.4%
Employees
10
Rev per Employee
$0.0

Bio-Path Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Bio-Path Holdings, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Bio-Path Holdings, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Bio-Path Holdings, Inc.

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.99 0.99
74% 74%
-
- Research and Development Expense 4.36 4.36
16% 16%
-
-5.35 -5.35
40% 40%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.35 -5.35
40% 40%
-
Net Profit -5.84 -5.84
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Path Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Head office United States
CEO Mr. Grover
Employees 10
Founded 2007
Website www.biopathholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today